Acurx Pharmaceuticals Announced The Presentation Of A Scientific Poster At The Infectious Diseases Society Of America IDWeek 2024 Conference
Acurx Pharmaceuticals Announced The Presentation Of A Scientific Poster At The Infectious Diseases Society Of America IDWeek 2024 Conference
Acurx Pharmaceuticals宣佈將在2024年美國傳染病學會(IDWeek)會議上展示科學海報。
- The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI)
- Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut
- Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)
- Preparing to submit requests for regulatory guidance to initiate clinical trials in the European Union to be followed by the United Kingdom, Japan and Canada
- Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA
- 所呈現的數據表明，有利的腸道膽汁酸譜系可能有助於伊貝扎泊斯他在患有C. difficile感染（CDI）患者中的有益抗復發效果
- 伊貝扎泊斯他治療CDI患者與腸道中有益細菌種類的恢復相關聯
- 準備繼續將伊貝扎泊斯他推進至國際第三階段臨床試驗，用於治療C. difficile感染（CDI）
- 準備提交申請，尋求在歐盟啓動臨床試驗的監管指導，隨後是日本、英國和加拿大
- 伊貝扎泊斯他先前已獲得FDA QIDP認定和FDA的快速通道認定
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間